Méroc Estelle, Fröberg Janeri, Almasi Timea, Winje Brita Askeland, Orrico-Sánchez Alejandro, Steens Anneke, McDonald Scott A, Bollaerts Kaatje, Knol Mirjam J
P95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001, Leuven, Belgium.
Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Laboratory of Medical Immunology, Section Paediatric Infectious Diseases, Geert Grooteplein 21, 6525 EZ, Nijmegen, the Netherlands.
BMC Infect Dis. 2021 Apr 13;21(1):345. doi: 10.1186/s12879-021-06017-7.
To guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.
We conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019.
Morbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC.
This study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.
为指导欧洲老年人群免疫规划的决策制定,“老年人群中的疫苗与传染病(IMI2 - VITAL)”项目的目标之一是评估(潜在)疫苗可预防疾病((P)VPD)的疾病负担(BoD)。我们旨在确定参与VITAL项目的国家中用于计算(P)VPD疾病负担的可用数据来源,并找出数据缺口。基于流行病学标准和疫苗可及性,我们将由肠道外致病性大肠杆菌(ExPEC)、诺如病毒、呼吸道合胞病毒、金黄色葡萄球菌和肺炎球菌性肺炎引起的(P)VPD列为优先研究对象。
我们对来自欧洲国家的专家进行了一项关于可用数据(如发病率、死亡率、伤残调整生命年(DALY)、质量调整生命年(QALY)、后遗症、抗菌药物耐药性(AMR)等)的调查,并通过检索MEDLINE获取2009年至2019年间发表的同行评审出版物,开展了五项针对特定病原体的文献综述。
所有五种疾病的发病率和死亡率数据一般均可获取,但大多缺乏疾病负担的汇总估计值。可用数据并不总是按年龄和风险组分层,而这在计算老年人群的疾病负担时尤为重要。几个国家有金黄色葡萄球菌和ExPEC的抗菌药物耐药性数据。
本研究全面概述了欧盟/欧洲经济区老年人群中五种(P)VPD疾病负担估计的可用数据来源和数据缺口,有助于指导针对特定病原体的疾病负担研究,并为计算(P)VPD的疾病负担做出贡献。